AstraZeneca has partnered with two Algerian companies, AHT Health SARL of SALHI group and Hasnaoui Finance SARL Group. The companies have created the joint venture AstraZeneca Al Djazair to build a new production unit in Algeria. This commitment, which will generate investments and skilled jobs, is part of the Algerian government’a strategy to modernize and develop the pharmaceutical sector of the country. The new facility would formulate AstraZeneca medicines in cardiovascular diseases, gastroenterology, oncology and diabetes for the Algerian healthcare community.
The health policy in Algeria allows fair access to care and treatment to all the Algerian population, which is a singularity in Middle East and Africa; Algeria is the only country across this region to have an universal healthcare access program that covers nearly all population. The economical stability, the open dialogue and the partnering opportunities allows AstraZeneca to provide better local infrastructures by investing and implementing in Algeria the regional office for AstraZeneca North West Africa.
AstraZeneca settled in Algeria in 2007 with a small team and currently has almost 180 employees.
With the investment reaching $125 million and creating around 104 direct jobs and 231 indirect jobs, AstraZeneca local production will bring a real transfer of technology and know-how in Algeria.